INT158581

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.43
First Reported 2005
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 7
Total Number 7
Disease Relevance 1.83
Pain Relevance 0.29

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

small molecule metabolic process (CYP3A4) oxidoreductase activity (CYP3A4) endoplasmic reticulum (CYP3A4)
enzyme binding (CYP3A4) lipid metabolic process (CYP3A4) cytoplasm (CYP3A4)
Anatomy Link Frequency
plasma 2
liver 2
CYP3A4 (Homo sapiens)
Pain Link Frequency Relevance Heat
carbamazepine 8 99.20 Very High Very High Very High
Versed 16 96.92 Very High Very High Very High
Bioavailability 5 88.36 High High
dexamethasone 31 84.40 Quite High
Serotonin 58 78.96 Quite High
antagonist 67 77.44 Quite High
noradrenaline 25 43.24 Quite Low
Potency 8 41.24 Quite Low
rapifen 8 40.56 Quite Low
lidocaine 4 28.44 Quite Low
Disease Link Frequency Relevance Heat
Injury 94 99.32 Very High Very High Very High
Toxicity 37 92.52 High High
Vomiting 220 91.68 High High
Acquired Immune Deficiency Syndrome Or Hiv Infection 96 89.28 High High
Necrosis 1 69.64 Quite High
Hepatotoxicity 13 63.24 Quite High
Increased Venous Pressure Under Development 1 62.80 Quite High
Hepatic Insufficiency 3 61.40 Quite High
Nephrotoxicity 2 55.92 Quite High
Autoimmune Disease 1 54.76 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Compared with reversible inhibition of CYP3A4, mechanism-based inhibitors of CYP3A4 more frequently cause pharmacokinetic-pharmacodynamic drug–drug interactions, as the inactivated CYP3A4 has to be replaced by newly synthesized CYP3A4 protein.
Negative_regulation (replaced) of Positive_regulation (inactivated) of CYP3A4
1) Confidence 0.43 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0 Pain Relevance 0.04
Importantly, mechanism-based CYP3A4 inactivation causes long-term effects on drug pharmacokinetics, as the inactivated CYP3A4 has to be replaced by newly synthesized CYP3A4 protein.
Negative_regulation (replaced) of Positive_regulation (inactivated) of CYP3A4
2) Confidence 0.43 Published 2005 Journal Therapeutics and Clinical Risk Management Section Body Doc Link PMC1661603 Disease Relevance 0.09 Pain Relevance 0
A pharmacokinetic interaction between ciprofloxacin and the patient's comedication carbamazepine is unlikely to be the responsible mechanism, since fluoroquinolones inhibit cytochrome P450 isoenzyme CYP1A2 but not CYP3A4 which metabolizes carbamazepine.
Negative_regulation (inhibit) of Positive_regulation (cytochrome) of CYP3A4
3) Confidence 0.41 Published 2009 Journal Int J Clin Pharmacol Ther Section Body Doc Link 19281725 Disease Relevance 0 Pain Relevance 0
In contrast with desvenlafaxine, the CYP2D6 genetic polymorphism has a significant influence on venlafaxine pharmacokinetics.122 Both drugs may have low potential for drug interactions, because of low protein binding and a relatively weak inhibitory effect on CYP isoenzymes.90,123 Nevertheless, increased plasma levels of imipramine, its metabolite desimipramine,124 and risperidone were associated with concomitant administration of venlafaxine.125 Furthermore, diphenhydramine may alter the disposition of venlafaxine via inhibition of CYP2D6.126 CYP3A4 inducers may enhance the clearance rate of desvenlafaxine.122
Negative_regulation (inhibition) of Positive_regulation (inducers) of CYP3A4 in plasma
4) Confidence 0.38 Published 2010 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2938284 Disease Relevance 0 Pain Relevance 0
Caution is also advised when giving concomitant inhibitors of CYP3A4 (such as ketoconazole, itraconazole, clarithromycin, ritonavir, and nelfinavir) which may increase aprepitant concentrations, and with inducers of CYP3A4 (such as rifampin, carbamazepine, and phenytoin) which may reduce its concentration.


Negative_regulation (inhibitors) of Positive_regulation (inducers) of CYP3A4 associated with carbamazepine
5) Confidence 0.34 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012554 Disease Relevance 0.31 Pain Relevance 0.22
Specifically, during glycerol-induced AKI in rats, there was a significant increase in CYP3A4 activity in the intestine despite a significant decrease in CYP3A4 activity in the liver.
Negative_regulation (decrease) of Positive_regulation (increase) of CYP3A4 in liver associated with injury
6) Confidence 0.22 Published 2008 Journal Crit Care Section Body Doc Link PMC2646335 Disease Relevance 1.02 Pain Relevance 0
Maraviroc is metabolized by CYP3A4, therefore dose adjustments will be required when it is used in combination with commonly used antiretroviral agents such as the PI ritonavir (an inhibitor of CYP3A4) and the NNRTI efavirenz (CYP3A4 inducer).
Negative_regulation (inhibitor) of Positive_regulation (inducer) of CYP3A4
7) Confidence 0.17 Published 2007 Journal Core Evidence Section Body Doc Link PMC3012555 Disease Relevance 0.40 Pain Relevance 0.03

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox